AI in surgery faces scrutiny as TruDi Navigation System linked to strokes and patient injuries

AI in Surgery Triggers Wave of Patient Injuries and Lawsuits

When Acclarent, a unit of healthcare giant Johnson & Johnson, announced in 2021 that it was adding artificial intelligence to its TruDi Navigation System for treating sinusitis, the company called it "a leap forward." The reality has proven far more troubling. Before the AI integration, the device had generated just seven unconfirmed malfunction reports to the US Food and Drug Administration over three years. After the machine learning algorithm was added, that number exploded to at least 100 malfunctions and adverse events, with at least 10 patient injuries reported between late 2021 and November 2025 1

1

.

The alleged injuries paint a disturbing picture of AI in surgery gone wrong. Most incidents involved the TruDi Navigation System providing incorrect information about instrument locations during operations inside patients' heads. One patient reportedly experienced cerebrospinal fluid leaking from their nose. In another case, a surgeon mistakenly punctured the base of a patient's skull. Two patients allegedly suffered strokes after major arteries were accidentally injured during sinuplasty procedures 1

1

.

Acclarent Lawsuits Challenge AI Safety Standards

Two stroke victims have filed Acclarent lawsuits in Texas, directly challenging the safety of AI-powered medical devices. Erin Ralph alleges the TruDi Navigation System misled her surgeon, Marc Dean, during a 2022 procedure, causing him to injure a carotid artery and resulting in a blood clot and stroke. Donna Fernihough's lawsuit describes her carotid artery allegedly "blowing" with blood spraying "all over," leading to a same-day stroke 3

3

.

Both cases make a striking claim: "The product was arguably safer before integrating changes in the software to incorporate artificial intelligence than after the software modifications were implemented" 1

1

. Fernihough's suit goes further, accusing Acclarent of implementing inadequate safety standards by setting "as a goal only 80 percent accuracy for some of this new technology before integrating it into the TruDi Navigation System," allegedly rushing the device to market 3

3

.

Integra LifeSciences, which acquired Acclarent and the TruDi system from Johnson & Johnson in 2024, disputes these claims. The company told Reuters that FDA reports "do nothing more than indicate that a TruDi system was in use in a surgery where an adverse event took place" and maintains "there is no credible evidence to show any causal connection between the TruDi Navigation System, AI technology, and any alleged injuries" 1

1

.

Medical Device Malfunctions Reveal Broader Pattern

The TruDi incidents represent just one troubling example in a rapidly expanding field. The FDA has now authorized at least 1,357 medical devices using AI—double the number approved through 2022 1

1

. Many have encountered serious problems. Researchers from Johns Hopkins, Georgetown, and Yale universities published findings in JAMA Health Forum showing that 60 FDA-authorized AI medical devices were linked to 182 product recalls. Alarmingly, 43% of these recalls occurred less than a year after approval—about twice the higher recall rate for AI devices compared to all devices authorized under similar FDA rules 1

1

.

Other botched surgeries and errors have emerged beyond the TruDi system. The FDA has received reports about an AI heart monitor that allegedly overlooked abnormal heartbeats. Sonio Detect, an AI system for analyzing fetal images, allegedly misidentified fetal body parts and incorrectly labeled structures, raising concerns about AI hallucinations in medical contexts 1

1

2

2

.

FDA Oversight Weakens as AI Devices Proliferate

The explosion of AI-powered medical devices comes at a precarious moment for FDA oversight. Five current and former agency scientists told Reuters that the FDA is struggling to keep pace with the flood of AI-enhanced devices seeking approval after losing key staff 1

1

. The Department of Government Efficiency cuts severely impacted the agency's AI review capacity, with the unit tasked with reviewing AI-enabled medical devices losing 15 of its 40 scientists. Another unit involved in AI in medicine lost one-third of its staff 2

2

.

"If you don't have the resources, things are more likely to be missed," a former device reviewer warned 3

3

. This resource crunch raises questions about patient safety as companies rush to integrate AI technologies. Many AI devices don't undergo clinical trials before FDA approval; instead, manufacturers point to previously authorized devices before adding AI capabilities through algorithm updates 3

3

.

What This Means for Healthcare's AI Future

The medical device industry's embrace of generative AI and machine learning technologies extends beyond surgical navigation. ChatGPT and similar large language models are entering healthcare through consumer apps and physician tools, while AI algorithms screen medical scans for diseases like cancer 3

3

. Yet the TruDi cases suggest that adding AI to established medical devices may introduce new risks that outweigh potential benefits.

The lawsuits allege that AI features served primarily as a "marketing tool" rather than genuinely improving accuracy 2

2

. This raises concerns about whether publicly traded companies like Johnson & Johnson face pressure to rush products to market without sufficient safety testing. As administrators like Mehmet Oz promote AI-powered ultrasounds and diagnostic "wands," the gap between technological enthusiasm and proven patient safety continues to widen 3

3

. Medical professionals and patients alike must now navigate an operating room landscape where skull punctures and strokes linked to software modifications demand answers about accountability and the true cost of innovation.